Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LTR PharmaASX:LTP -1.10%7 Earnings per Share (Diluted) is A$-0.05 as of Dec. 2025. GuruFocus rates ASX:LTP with a GF Score™ of 7/100. Among 1,166 Biotechnology companies, LTR Pharma ranks worse than 96.57% on this metric.
LTR Pharma's EPS (Basic) for the
six
months ended in Dec. 2025 was A$-0.03.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.05.
LTR Pharma's EPS without NRI for the
six
months ended in Dec. 2025 was A$-0.03.
Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.05.
During the past 3 years, the average EPS without NRIGrowth Rate was -67.70% per year.
During the past 5 years, LTR Pharma's highest 3-Year average EPS without NRI Growth Rate was -67.70% per year. The lowest was -67.70% per year. And the median was -67.70% per year.
LTR Pharma (ASX:LTP) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
LTR Pharma Earnings per Share (Diluted) Related Terms
LTR Pharma Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for LTR Pharma's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:LTP vs VRTX, REGN, RVMD: Earnings per Share (Diluted) Comparison
For the Biotechnology subindustry, LTR Pharma's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LTR Pharma PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, LTR Pharma's PE Ratio distribution charts can be found below:
* The bar in red indicates where LTR Pharma's PE Ratio falls into.
LTR Pharma Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
LTR Pharma's Earnings Per Share (Diluted) for the fiscal year that ended in Jun. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.05
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of A$-0.05 mean?
LTR Pharma (ASX:LTP) has a Earnings per Share (Diluted) of A$-0.05 as of Dec. 2025. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on LTR Pharma and its competitors. According to the industry distribution chart, LTR Pharma ranks #1126 out of 1166 companies in the Biotechnology industry, placing it in the top 96.6%.
Is LTR Pharma's Earnings per Share (Diluted) too high?
LTR Pharma's current Earnings per Share (Diluted) is A$-0.05. Based on the distribution chart, LTR Pharma ranks #1126 out of 1166 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, LTR Pharma has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does LTR Pharma's Earnings per Share (Diluted) compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, LTR Pharma ranks #1126 out of 1166 companies for Earnings per Share (Diluted). This places LTR Pharma in the lower half of its industry. The industry median Earnings per Share (Diluted) is 16.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Biotechnology company?
The median Earnings per Share (Diluted) among Biotechnology companies is 16.20, based on 1,166 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on LTR Pharma and its competitors. For the Biotechnology industry, the median Earnings per Share (Diluted) is 16.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LTR Pharma's current Earnings per Share (Diluted) is A$-0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LTR Pharma stock overvalued right now?
LTR Pharma (ASX:LTP) has a current Earnings per Share (Diluted) of A$-0.05. The current Earnings per Share (Diluted) is A$-0.05. LTR Pharma's overall GF Score™ is 7/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For LTR Pharma (ASX:LTP), the current Earnings per Share (Diluted) is A$-0.05 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on the market.
7GF Score
Get the complete analysis for ASX:LTP
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:LTP has been successfully added to your 
